Phase I Trial of Oral PX-866
This study is being conducted to determine the safety and maximally tolerated dose of PX-866 when given orally on two different schedules: daily on days 1-5 and 8-12 of a 28 day cycle and daily on days 1-28 of a 28 day cycle.
Advanced Solid Tumors
DRUG: PX-866
Determine the MTD of PX-866, 28 days|Evaluate the safety profile of PX-866, 28 days|Evaluate pharmacodynamic measures of the effects of PX-866 on the phosphatidylinositol-3 kinase (PI-3K) pathway and related tumor markers., 28 days|Determine the PK profile of PX-866., 28 days
Evaluate the anti-tumor activity of PX-866 in patients with advanced malignancies., 56 days
PX-866 is a targeted inhibitor of PI-3K. This study is being conducted to determine the maximally tolerated dose of PX-866 when given orally on two different schedules: daily on days 1-5 and 8-12 of a 28 day cycle and daily on days 1-28 of a 28 day cycle.